Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer |
| |
| Authors: | Takashi Yoshioka Yuh Sakata Masanori Terashima Kouji Sekikawa Makio Gamoh Yasushi Mitachi Soh Saitoh Ryunosuke Kanamaru |
| |
| Affiliation: | (1) Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan;(2) Misawa City Hospital, Misawa, Japan;(3) Iwate Medical University, Morioka, Japan;(4) Fukushima Medical University, Fukushima, Japan;(5) Ogawara Municipal Hospital, Ogawara, Japan;(6) Sendai Kousei Hospital, Sendai, Japan;(7) Aomori Prefectural Central Hospital, Aomori, Japan |
| |
| Abstract: | Background. Both docetaxel (TXT) and irinotecan (CPT-11) are active chemotherapeutic agents for gastric cancer. We designed a biweekly administration regimen of TXT combined with CPT-11 for 4 weeks as one cycle in patients with inoperable or recurrent gastric cancer, and conducted a dose-escalation study. Methods. Patients with histologically confirmed gastric cancer were treated with the regimen. The dosage levels of TXT and CPT-11 were as follows: level 1, 30 mg/m2 and 50mg/m2; level 2, 35 and 50mg/m2; level 3, 40 and 50mg/m2; level 4, 40 and 60mg/m2; and level 5, 50 and 60mg/m2. The dose escalation was based on the dose-limiting toxicity (DLT) observed during the first cycle. Results. Grade 4 neutropenia was observed at level 3, but no other DLT was observed at less than level 4 during the first cycle. However, three patients at level 3 could not continue treatment without a decrease in the dosage after the second cycle. Based on these results, level 2 was considered to be the clinically recommended dosages. Conclusion. Biweekly TXT and CPT-11 was well tolerated. The recommended dosages of TXT and CPT-11 for a phase II trial are 35mg/m2 and 50mg/m2, respectively. |
| |
| Keywords: | Chemotherapy Docetaxel (TXT) Gastric cancer Irinotecan (CPT-11) |
| 本文献已被 SpringerLink 等数据库收录！ |
|
